The Mylan EpiPen Debacle: How Tremendous Greed Can Lead to the Demise of a Leader
N2Growth Blog
AUGUST 30, 2016
Through shrewd marketing efforts, failed competitors and helpful legislation (which requires its availability at public schools), Mylan has cornered the market on this allergy medication. ” “The reality is and the brand pharmaceutical market, this isn’t an EpiPen issue. So $137 per pen.
Let's personalize your content